Comparison · NCT01173523-sae
Cohort A: STA-9090 vs Cohort B: STA-9090: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort A: STA-9090 vs Cohort B: STA-9090: serious adverse events. Trial comparisons, record NCT01173523-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01173523-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.308 | 0.127 | 0.576 | wilson | |
| Risk in group 2 | 0.25 | 0.0889 | 0.532 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0577 | -0.278 | 0.371 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.344 | 4.4 | log | |
| Odds ratio, group 1 over group 2 | 1.33 | 0.23 | 7.74 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Cohort A: STA-9090 than on Cohort B: STA-9090 | 17.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort A: STA-9090 | Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed \> 60 days following initial chemotherapy completion. | 4 | 13 | EG000 |
| Group 2 | Cohort B: STA-9090 | Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed \</= 60 days from the completion of initial chemotherapy. | 3 | 12 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Assessed weekly on treatment from time of first dose and up to day 30 post-treatment. Treatment duration was a median of 2 cycles (parallel to 2 months given the 4 week cycle length) and range of 1-2 cycles.
Source ClinicalTrials.gov
Trial
- Title
- Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
- NCT number
- NCT01173523
- Phases
- PHASE2
- Conditions
- Small Cell Lung Cancer
- Interventions
- STA-9090
- Lead sponsor
- David M. Jackman, MD
- Results first posted
- 2017-04-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01173523?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01173523-sae